Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Sullivan

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Oncotarget|June 15, 2017
Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironmentGemma Shay, Marilena Tauro, Fulvio Loiodice, et al.
Molecular Cancer Therapeutics|December 17, 2010
Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effectMing Li, Feng Chen, Nicholas Clifton, et al.
Oncotarget|March 9, 2018
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancerHatem Soliman, Fatema Khambati, Hyo S Han, et al.
Structure (London, England : 1993)|November 13, 2008
Insights into the nature of DNA binding of AbrB-like transcription factorsDaniel M Sullivan, Benjamin G Bobay, Douglas J Kojetin, et al.
Cancer Research|May 19, 2006
Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usageTakeo Nakanishi, Kimberly J Bailey-Dell, Bret A Hassel, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 13, 2015
Effect of Age on Clinical Outcomes in Phase 1 Trial ParticipantsAmit Mahipal, Aaron C Denson, Benjamin Djulbegovic, et al.
Cancer Research|August 20, 2009
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibitionJoel G Turner, Douglas C Marchion, Jana L Dawson, et al.
Biochemistry|July 1, 2008
Co-evolving motions at protein-protein interfaces of two-component signaling systems identified by covariance analysisHendrik Szurmant, Benjamin G Bobay, Robert A White, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Oncotarget|June 15, 2017
Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironmentGemma Shay, Marilena Tauro, Fulvio Loiodice, et al.
Molecular Cancer Therapeutics|December 17, 2010
Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effectMing Li, Feng Chen, Nicholas Clifton, et al.
Oncotarget|March 9, 2018
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancerHatem Soliman, Fatema Khambati, Hyo S Han, et al.
Structure (London, England : 1993)|November 13, 2008
Insights into the nature of DNA binding of AbrB-like transcription factorsDaniel M Sullivan, Benjamin G Bobay, Douglas J Kojetin, et al.
Cancer Research|May 19, 2006
Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usageTakeo Nakanishi, Kimberly J Bailey-Dell, Bret A Hassel, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 13, 2015
Effect of Age on Clinical Outcomes in Phase 1 Trial ParticipantsAmit Mahipal, Aaron C Denson, Benjamin Djulbegovic, et al.
Cancer Research|August 20, 2009
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibitionJoel G Turner, Douglas C Marchion, Jana L Dawson, et al.
Biochemistry|July 1, 2008
Co-evolving motions at protein-protein interfaces of two-component signaling systems identified by covariance analysisHendrik Szurmant, Benjamin G Bobay, Robert A White, et al.
Pageof 9